As noted in our July 10, 2017 story, Bioverativ has filed complaints in the U.S. District Court for the District of Delaware and with the U.S. International Trade Commission alleging that Idelvion, a novel factor IX albumin fusion protein developed by CSL Behring, infringes upon three Bioverativ patents.
HFA, in collaboration with the National Hemophilia Foundation, the Coalition for Hemophilia B, and the Committee of Ten Thousand, in addition to numerous local and state bleeding disorders advocacy organizations have submitted a letter to the U.S. International Trade Commission outlining our concerns that patients have unfettered access to the care and treatments they need. We will NOT be engaging in the dialogue around patent ownership and will not be “choosing a side” relative to these litigations, rather, we will remained focused on patient access to treatment.
As a patient advocacy organization, we will be speaking to the use, public health, safety, and welfare concerns on United States consumers and will continue to work to ensure patient access to FDA approved products.
